Estramustine versus conventional estrogenic hormones in the initial treatment of highly or moderately differentiated prostatic carcinoma. A randomized study.
In a prospective randomized multicenter trial patients with highly or moderately differentiated prostatic carcinoma, previously untreated, were allotted either to oral Estramustine phosphate or to intramuscular polyestradiol phosphate plus oral ethinyl estradiol. As regards frequency and duration of tumour remission there was no statistical difference between the two groups. Nor did they differ significantly with respect to adverse reactions. This is an interim report and will be followed later on by a final evaluation.
D001859:Bone Neoplasms / Q000556:secondary; D004961:Estramustine / Q000009:adverse effects / Q000627:therapeutic use*; D004967:Estrogens / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use*; D010744:Phosphoric Monoester Hydrolases / Q000097:blood; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D011897:Random Allocation
D004967:Estrogens; D009588:Nitrogen Mustard Compounds; D004961:Estramustine; D010744:Phosphoric Monoester Hydrolases